54
GileadLitigation
InAugust 2013, GileadSciences Inc. filed a suit in theUnitedStatesDistrict Court of theNorthernDistrict ofCalifornia
related toUnitedStates PatentNos. 7,105,499 and8,481,712 that are jointlyownedbyMerckSharp&DohmeCorp. and Isis
Pharmaceuticals, Inc. In the suit Gilead is asking the court todetermine that Gilead’s activities donot infringe anyvalid claimof the
named patents and that the patents are not valid. Isis andMerckSharp&DohmeCorp. filed their answer denyingGilead’s
noninfringement and invalidity contentions, contending thatGilead’s commercial sale andoffer for sale of sofosbuvir prior to the
expirationof the ‘499 and ‘712patentswill infringe those patents, and requestingmonetary damages to compensate for such
infringement. Under Isis’ agreementwithMerck,Merck is responsible for the costs of this suit.
Item4. MineSafetyDisclosures
Not applicable.
PART II
Item5. Market forRegistrant’sCommonEquity, RelatedStockholderMatters and IssuerPurchases of EquitySecurities
Our common stock is tradedpublicly throughTheNasdaqGlobal SelectMarket under the symbol “ISIS.”The following
table presents quarterly information on the price range of our common stock. This information indicates the high and low sale prices
reportedbyTheNasdaqGlobal SelectMarket. These prices donot include retailmarkups,markdowns or commissions.
HIGH
LOW
2013
First Quarter ............................................................................................ $
19.53 $
10.36
SecondQuarter ....................................................................................... $
28.66 $
15.92
ThirdQuarter .......................................................................................... $
39.83 $
23.63
FourthQuarter ........................................................................................ $
42.69 $
29.41
2012
First Quarter ............................................................................................ $
9.28 $
7.08
SecondQuarter ....................................................................................... $
12.00 $
7.02
ThirdQuarter .......................................................................................... $
15.61 $
11.45
FourthQuarter ........................................................................................ $
14.36 $
7.56
As of February21, 2014, therewere approximately719 stockholders of recordof our common stock.We have never paid
dividends anddonot anticipate paying anydividends in the foreseeable future.
Set forth below is a table and chart comparing the total returnon an indexed basis of $100 invested onDecember 31, 2008 in
our common stock, theNASDAQComposite Index (total return) and theNASDAQBiotechnology Index. The total return assumes
reinvestment of dividends.
